To donate to NanoBiotech Pharma's Medical Research: Enter amount in $US in box, then click on Donate:

The Treatable & Reversible Infectious Cause of Pathological Calcification, Vascular Plaque,

Coronary Artery Disease & Many Chronic Diseases

Over the past 15 years our research has firmly established that Calcifying Nanoparticles (aka CNP/NP/Nanobacteria) infection is the cause of  pathological calcification, a mediator of vascular & tissue plaque deposits, the direct cause of calcium oxalate stones (wherever found) and an agent of inflammation. CNP infection (calcification, plaque and inflammation) is treatable and is reversible with our targeted Nanobiotics. CNPs are unique infectious agents similar to other "non-living" infectious agents such as Viruses and Prions. Wherever pathological calcification can be found in the human body, whether in blood vessels or tissues....research shows that it is caused by CNPs. CNP infection results in calcified heart valves and coronary artery plaque and arteriosclerotic vascular plaque from head-to-toe. CNP infection is also the cause of kidney stones, gallstones, IC, BPH and Prostatitis. CNP infections have been shown to cause premature births and fetal miscarriages. CNPs are also involved in the development Alzheimer's, MS and SLE in our nervous systems and Scleroderma, Psoriasis, Eczema & arthritis in our skin and joints. CNPs are also directly-linked with many cancers. CNPs are 25-200 nanometers in size, reproduce very slowly, cause RNA & DNA replication errors and cell-death (apoptosis). They are difficult to observe due to their extremely small size (require electron microscope); are involved in thrombotic blood clotting cascades and ruptured vulnerable vascular plaque. We have no successful means of defeating a CNP infection. Our only immune defense against CNPs is to encase & surround the areas of CNP infection (like the walling-off of a cyst), but even then, our attempts to isolate the CNP infection only serve to temporarily slow down CNP infectious processes. CNPs override and defeat our best immune responses, causing their infectious cascades to wax, wane and continue unabated. Our researchers discovered CNPs and have personally conducted or directed all Worldwide CNP research. There are currently hundreds of CNP scientific and clinical papers published in prestigious journals. We are the established CNP experts. Our anti-CNP Nanobiotics: NanobacTX, Urobac, Dermabac & RegenurEYES are the targeted treatments that end CNP infections in different systems. 

Over our lifetime, arteriosclerotic plaque develops in our arteries, increasing at the rate of ~44% per year. This plaque slowly decreases bloodflow to our tissues and organs causing these organs to get smaller, this atrophy (for example) causes decreases in output of hormones from our endocrine organs - and this process is called AGING. At some point the calcified plaque in our heart worsens to become unstable vulnerable plaque that IS Coronary Artery Disease (CAD), the #1 cause of death. "We know that 70% of heart attacks are caused by unstable plaque, so what we really need for our patients is a way to identify the plaque that turns evil and puts them at jeopardy.” says Mayo Clinic cardiology researcher Birgit Kantor, M.D., PhD. Calcified coronary artery plaque is eventually "vulnerable" and primed for rupture, meaning that the plaques can burst open (like a cyst or pimple) from inflammation & pressure with the contents flying into the coronary blood stream. Ruptured calcified plaque debris in the bloodstream starts a messy blood-clotting cascade of events that can cause a heart attack, stroke or death. In 40% of patients that die from heart attack....their first symptom was death.

In late 1996, endovascular researcher (our Founder), Gary S. Mezo invented NanobacTX, a patented OTC compound designed to safely decrease calcified coronary artery plaque volume (Heart Disease) by safely dissolving it. After arteriosclerotic plaque volume is eliminated, our arteries are functionally & structurally in a more youthful "pre-heart-disease" state....where heart disease plaque no longer exists to threaten a heart attack or stroke.

 NanobacTX - the first Nanobiotic

NanobacTX is a patented OTC nanobiotic compound effective in treating CNP infection, arteriosclerotic plaque and pathological calcification. NanobacTX is shown in published clinical studies to be effective in reversing the physical effects of Coronary Artery Disease, heart disease and other vascular-mediated conditions by dissolving the calcified arteriosclerotic plaque. Dissolving arteriosclerotic plaque allows bloodflow to return to normal, thereby alleviating symptoms of coronary artery disease, markedly improving exercise capacity and functional ability. It is of value in those with existing heart disease of any severity and also as a preventive measure in those with a genetic or family predisposition to develop heart disease.

In published clinical studies by cardiologists, 6 months therapy with NanobacTX showed physical and functional improvement in coronary artery disease (CAD).....many patients in our studies were able to reduce or completely eliminate their need for heart medications that were previously required. Exercise tolerance (capacity/ability) was greatly increased and anginal chest pain and many other symptoms of heart disease were either greatly reduced or eliminated. To read the full published studies on NanobacTX done at MAYO, NASA, UCSD, USC and many others.....Just click on the NanobacTX Page in the left column under the heading "Our Nanobiotics".

A NanobacTX Testimonial (just one of many) - "My first heart scan June 29th showed a total Coronary Artery Calcification (CAC) score of 2,149 which is an abnormal level and a severely dangerously high score that says I'm at high-risk for a heart attack or stroke. After taking the NanobacTX therapy for about 47 weeks my CAC score decreased to 548.8. My physical well-being has improved and I am now feeling more energetic during work and exercise. Equally important, I am feeling better emotionally, knowing that my CAC had dropped from abnormal/severe to a more moderate-risk. I believe that had the NanobacTX therapy existed in 1988, I may have avoided my quadruple by-pass surgery." -G.K. (patient)

~Alzheimer's Disease & NanobacTX: "Dementia & Alzheimer's are words that denote different states of cognitive decline secondary to arteriosclerotic damage. Vascular plaque (bAmyloid + brain-sand calcification) leads to progressive tissue atrophy, end-organ atrophy and neurological dysfunction. Genetic variances in individuals ultimately predispose a person to various levels of immune response to the inflammation caused by the CNP infection. We have reports of dramatic Alzheimer's improvement while being treated with NanobacTX. One testamonial: "My sister was treated with NanobacTX for her heart disease for 4 months. Not only did her heart disease get better, but so did her Alzheimer's Disease! She was confined to a nursing home for her Alzheimer's Disease as she was no longer capable of caring for herself at home. She did not even know who we were were! But after 4 months of NanobacTX, she knew who we were, and was able to return to her own home and live by herself successfully with her Alzheimer's symptoms completely gone!" - R.F. 

UROBAC - Our second Nanobiotic

Urology researcher, Daniel Shoskes, MD (CLEVELAND CLINIC) from his Chronic Prostatitis UROBAC study published in the Journal of UROLOGY: “We treated a group of patients with prostatic stones and long-standing CPPSIII symptoms unresponsive to conventional therapies with a treatment (UROBAC) designed to eliminate stone forming nanobacteria and found that 80% had a significant improvement in symptoms (and stones dissolved) after 3 months"...."the study population represented a truly hard-core group of patients in whom multiple previous therapies had failed, including antibiotics, phytotherapy, a-blockers, neuromuscular therapies and prostatic massage. A response of such magnitude even in an uncontrolled study is noteworthy in this patient population.”

~UROBAC for KIDNEY STONES: Kidney Stones are comprised of pathological calcification as well. Our UROBAC Kidney Stone research was done at NASA, Mayo Clinic, UofI, UCSF and many others. UROBAC is also designed to dissolve kidney stones painlessly in situ....dissolving the stones so they are smooth and smaller and can pass with less pain or no pain. Our studies show that the calcific nidi of kidney stones at Randall's Plaques are eliminated, stopping most/all future stone generation. We also recommend the use of UROBAC instead of Lithotripsy for non-emergency therapy for kidney stones. For emergency treatment of kidney stones, recommend the use of Urobac pre-lithotripsy and post-lithotripsy which allows for smoother passage of fragments and more rapid clearing of fragments.

~UROBAC for PKD:The Studies have also shown UROBAC to stabilize, slow or halt the progression of PKD cysts. Review the published studies by clicking on on our UROBAC Page in the left column.

~UROBAC for GALLSTONES: Gallstones are also comprised of calcification and in many cases are effectively dissolved with UROBAC, obviating the need for cholecystectomy surgery in asymptomatic gallstones and eliminating the cancer-risk of leaving the stones in place until the patients are symptomatic.

DERMABAC - Our third Nanobiotic

Currently, most dermatology disorders are treated with either topical or oral corticosteroids or dangerous immune-suppressing monoclonal antibodies (MAB), therefore suppressing the body's response to the inflammatory cause of the rash.....in other words, treating the symptoms and not the underlying cause of the inflammatory disorder!

DERMABAC has been specifically developed to treat/eradicate the underlying inflammatory infectious cause of many of the most troublesome chronic dermatological disorders that our research has shown share two things in common: a genetic pre-disposition for the disease in most cases and an inflammatory trigger/cause. Dermabac is designed to eliminate or markedly decrease the visible symptoms and presence of plaques, redness, inflammation, swelling and tissue calcification that are hallmarks of many chronic dermatological disorders, such as eczema, psoriasis, atopic dermatitis, lichen planus, scleroderma and calcinosis cutis. DERMABAC directly targets the underlying pathological cause of calcific inflammation in these diseases in genetically pre-disposed patients. Read Finnish dermatopathologist Rauno Harvima, MD PhD's research by clicking on the DERMABAC Page in the left column.  

TO ORDER, go to the respective NanobacTX, Urobac, Dermabac or RegenurEYES pages.

      CLICK the FOX NEWS Video to view: